|Monday Breakfast||Monday Afternoon||Tuesday Breakfast|
Challenging the standard approach to managing chronic pain
A case study based discussion on complex chronic pain patients: how to manage, re-motivate and improve their functional outcomes.
|Associate Professor Tillman Boesel
Consultant Anaesthetist, Macquarie University Hospital
Pain Management Specialist, Western Sydney Pain Centre & Inner West Pain Centre
|Dr Tim Ho
Rehabilitation and Pain Specialist, Sydney Pain Management Centre
|Mr Tony Merritt
Clinical Psychologist, Western Sydney Pain Centre and Inner West Pain Centre
Further information coming soon....
Ketamine and buprenorphine – Old analgesics in a novel sublingual formulation
Ketamine is being used extensively in pain management, however, its optimal use remains to be determined. The clinical scenarios in which ketamine can be given are constrained by the only licensed formulation being an injection. Sublingual administration of ketamine by lozenges or rapidly dissolving sublingual wafers (Wafermine™) can provide rapid onset and effective pain reduction.
Despite proven clinical utility, buprenorphine has not been used widely for the treatment of acute and chronic pain. Mounting evidence from clinical studies strongly support superior safety and efficacy profile of buprenorphine versus other marketed opioids. BnoX™ is a novel sublingual buprenorphine wafer currently in clinical development.
In this talk, Professor Stephan Schug will summarise the literature on the use of ketamine and buprenorphine in pain management, and describe his experience with ketamine administered sublingually. Dr Janakan Krishnarajah will then share the latest clinical trial data for Wafermine™ and BnoX™ sublingual wafers.
Professor Stephan Schug is a Professor and Chair of Anaesthesiology in the School of Medicine and Pharmacology at the University of Western Australia. He is also the Director of Pain Medicine at the Royal Perth Hospital and is responsible for overseeing the Comprehensive Inpatient Pain Service, as well as a multi-disciplinary Pain Medicine Centre. The latter has been accredited for training by the Faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists.
Professor Schug is a Scientific Advisor to iX Biopharma. He also holds a position as Honorary Professor of Anaesthesiology at the University of Auckland, New Zealand.
Dr Janakan Krishnarajah is a Consultant Physician with specialist interests in Clinical Pharmacology and Internal Medicine now in private practice. He is a Fellow of the Royal Australasian College of Physicians.
Dr Krishnarajah was most recently the CEO and Medical Director of Linear Clinical Research, a leading Australian early phase clinical trials facility. He has extensive experience in phase I-IV clinical trials and has acted as Principal or Co-Investigator in over 100 Phase I/II clinical trials. He is a reviewing panel member of the Clinical Drug Trials Committee at Sir Charles Gairdner Hospital in Western Australia.
Dr Krishnarajah also has experience in the commercialization of new technologies within the biotechnology industry in venture capital backed start-up environments including acting as an Investment Advisor for Brandon Capital, an Australian life science focused VC.
As the Chief Medical Officer at iX Biopharma, Dr Krishnarajah is responsible for the development and implementation of clinical trial programmes.
Do great minds really think alike or...?
An interactive breakfast session to discuss “Complex Pain & Addiction Conundrums and Crossovers”.
Dr Martyn Lloyd-Jones is an addiction medicine specialist who has worked in the alcohol and drug field for over 16 years. He has worked in leadership roles in private practice settings as well as in public hospital and community clinics and is actively involved in medical education and clinical research. He has been a regular presenter at national and international conferences and reviewer for a number of peer reviewed journals as well as providing expert opinion to the media on addiction related matters. He has a particular interest in decreasing the stigma of substance use and developing new treatment paradigms for individuals with addictive disorders including the provision of compulsory treatment in the AOD environment.
Professor Stephan Schug is Professor and Chair of Anaesthesiology in the Department of Pharmacology, Pharmacy and Anaesthesiology of the University of Western Australia, Perth, Australia and Director of Pain Medicine at Royal Perth Hospital, Australia. His principal research interests include the management of acute and chronic pain, cancer pain, regional anaesthesia, the pharmacology of local anaesthetics and analgesics and quality improvement in health care.
Real World experience with Tapentadol - the Australian Experience
Dr Russo will discuss the findings of his recent paper "The Effectiveness and tolerability of tapentadol sustained release in the Australian setting" Marc A. Russo, MBBS, DA(UK), FANZCA, FFPMANZCA, Danielle M. Santarelli, PhD.
Dr Marc Russo is the Director of the Hunter Pain Clinic, Hamilton Day Surgery Centre, Hunter Clinical Research and Co-Director of the Innervate Pain Management Program in Newcastle NSW Australia. Dr Russo is the founding member and immediate past President of the Australian Chapter of the International Neuromodulation Society. He is the current 2013-15 Secretary of the International Chapter of Neuromodulation Society and resides on advisory boards, scientific advisory boards and committees, both nationally and internationally.